Table 1

Proviral DNA at baseline (week 0) and weeks 12, 24 and 48 after rhGH immunotherapy.

Proviral DNA, HIV-1 copy number/μg of total DNA

Patient^a

Baseline

Week 12

Week 24

Week 48

1 B

ND

8

ND

16

2 C

111

17

ND

46

3 C

476

853

711

625

4 B

536

452

307

220

5 A

55

46

50

52

6 A

223

359

99

93

7 C

315

150

83

238

8 B

42

83

28

57

9 B

91

103

35

56

10 C

15

1212*

750*

ND

11 A

363

3926*

1830*

2277*

12 A

48

27

336*

138

Mean ± sem

206 ± 56.6

603 ± 321.3

433 ± 178.2

347 ± 199.9

Median

111

127

203

93

(Range)

(15–536)

(8–3926)

(28–1830)

(16–2277)

^a Randomisation group at week 12 to 24: A – placebo recipients; B – alternate day dosing; and C – twice weekly dosing. ND – Not Done. *Notable increase.

Herasimtschuk et al. Journal of Immune Based Therapies and Vaccines 2008 6:7   doi:10.1186/1476-8518-6-7